Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2017-03-10 Regulatory Filings
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease
Regulatory Filings Classification · 95% confidence The document is a press release dated March 10, 2017, announcing the initiation of two new Phase 2 clinical studies for the drug filgotinib in Crohn's disease. It details the study designs, patient populations, primary endpoints, and provides background information on the disease and the company (Galapagos NV). This type of announcement, detailing clinical trial progress and pipeline updates, is characteristic of communications aimed at investors and the market regarding drug development. It is not a full Annual Report (10-K), an Earnings Release (ER) focusing on financial performance, or a formal Audit Report (AR). Since it is a specific announcement about clinical development and partnership activities, it fits best under a general category for corporate/investor news that isn't strictly financial results or management changes. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a press release detailing clinical trial updates, as there isn't a specific 'Clinical Trial Update' code. However, since it is a formal announcement of corporate activity, and not a miscellaneous filing, I will re-evaluate. It is an announcement of corporate/pipeline progress. Since it is a press release announcing clinical trial progress, and not a formal regulatory filing like a 10-K or a specific financial report, it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were a slide deck, but it is a text release. Given the nature of the content (drug development news), RNS (Regulatory Filings/General Announcement) is the standard catch-all for non-standard press releases.
2017-03-10 English
New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease
Regulatory Filings Classification · 95% confidence The document is a press release dated March 10, 2017, announcing the initiation of two new Phase 2 clinical studies for the drug filgotinib in Crohn's disease. It details the study designs, objectives, and provides background information on the disease and the company (Galapagos NV). This type of announcement, focusing on clinical trial progress and pipeline updates, is characteristic of communications aimed at investors and the market regarding ongoing research and development activities. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive quarterly report (IR). Since it is a specific announcement about clinical development and investor-facing information, the most appropriate category is Investor Presentation (IP), as these press releases often accompany or serve as brief updates similar to presentation material, or potentially Regulatory Filings (RNS) if it were a general announcement. However, given the specific focus on clinical trial initiation and pipeline progress, it aligns best with the intent of an Investor Presentation or a general corporate update that isn't strictly financial results or governance. Since there is no specific 'Clinical Trial Update' code, and it is a detailed announcement rather than just a link to a report (ruling out RPA), it is best classified as an Investor Presentation (IP) as it provides detailed information intended for investors about the drug pipeline.
2017-03-10 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV. It references a press release dated March 10, 2017, attached as Exhibit 99.1. The text indicates this is a report of a foreign private issuer pursuant to SEC rules, and the main content is a press release. The document length is short (2569 characters), and it primarily serves as an announcement of the press release rather than containing detailed financial data or a full report. According to the rules, such filings that are announcements or contain press releases are best classified as Regulatory Filings (RNS).
2017-03-10 English
Galapagos reports strong financial results and newsflow-rich pipeline
Earnings Release Classification · 98% confidence The document is dated February 23, 2017, and presents 'Key 2016 results' including revenues, operating loss, net profit, and cash balance, along with financial guidance for 2017. It explicitly states, 'Galapagos NV (Euronext & NASDAQ: GLPG) presents financial results and highlights the key events for the full year 2016.' This content structure—summarizing the full year's performance immediately following the year-end—is characteristic of an Earnings Release (ER) or a preliminary announcement preceding the full Annual Report (10-K). The document also mentions the upcoming publication of the 'fully audited Annual Report for the full year 2016 on or around 24 March 2017.' Since this document provides the key financial highlights and results announcement before the final audited report is available, it fits the definition of an Earnings Release (ER). It is not the full 10-K, nor is it just a short announcement of a report (RPA/RNS), as it contains substantial financial tables and management commentary. FY 2016
2017-02-24 English
Galapagos reports strong financial results and newsflow-rich pipeline
Audit Report / Information Classification · 98% confidence The document contains detailed, structured financial tables including the 'Consolidated Statement of Operations and Consolidated Statement of Comprehensive Income', 'Consolidated Statement of Financial Position', 'Consolidated Cash Flow Statement', and 'Consolidated Statement of Changes in Equity'. These statements cover full fiscal years (ended 31 December 2016 and 2015) and present comprehensive financial performance and position data. This structure and content are characteristic of a full Annual Report, which corresponds to the SEC's Form 10-K filing, even if the document itself is not explicitly labeled '10-K'. Since it is a comprehensive annual financial report, '10-K' is the most appropriate classification among the provided options, as opposed to 'IR' (Interim Report) or 'ER' (Earnings Release, which is usually just highlights). The document length (15,283 chars) confirms it is a substantial report, not a brief announcement. FY 2016
2017-02-24 English
Galapagos rapporteert sterke jaarcijfers en een veelbelovende pijplijn
Annual Report Classification · 100% confidence The document contains comprehensive consolidated financial statements, including the income statement, balance sheet, cash flow statement, and statement of changes in equity for the years 2015 and 2016. It provides detailed financial data rather than just a summary or announcement. Given the depth of the financial reporting and the inclusion of full statements, it is classified as an Annual Report (10-K). FY 2016
2017-02-24 Dutch

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.